We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Website
Linkedin

ORCID
https://orcid.org/0000-0002-2342-8531

Yama F Mujadidi

BCA Computer Application , MSc in Information Technology and Software Engineering

Programming and Data Management Director

Automation and Semantic Interoperability in Clinical Trials

Yama F Mujadidi has expertise in the design and development of software and is currently working with Oxford Vaccine Group in the capacity of Clinical Trials IT and Development Lead. He acquired an MSc in Information Technology from University of Bradford United Kingdom, in 2012 after he earned a First class degree in BCA Computer Application from the University of Pune, in the year 2010.
Yama joined Oxford Vaccine Group in June 2013 and tasked to provide specialist advice to research groups to improve quality of clinical trials and to develop an application based on the vaccine knowledge project for use in smart-phones/tablets. Before Oxford Vaccine Group, He had been working with Omni Communication Product Limited as a software developer and contributed to the development of a multi-communication application for use in smartphones and tablets.

Recent publications

8-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in children in Nepal (TyVOID): a prospective cohort follow-up study of the TyVAC Nepal randomised controlled trial.

Pant D. et al, (2027), Lancet Glob Health

Impact of dosing interval on immunogenicity following a heterologous typhoid conjugate vaccine booster in Nepalese children: An observational study

Zhang Y. et al, (2026), Journal of Infection, 93

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses

Ebrahimi N. et al, (2026), Vaccine, 88

COVID-19 vaccine effectiveness and SARS-CoV-2 variants in Nepal: Test-negative case-control study and genetic sequencing (COVVAR Nepal)

Pokhrel B. et al, (2026), Vaccine X, 31

Studying Early Life Live-Attenuated influenza virus immune Responses (STELLAR): study protocol for an exploratory observational study of the nasal mucosal and systemic immune response in healthy children given an intranasal live-attenuated influenza vaccine

Kelleher K. et al, (2026), BMJ Open, 16

The association between vaccine coverage and herd protection: exploratory analyses of a cluster-randomised trial of Vi conjugate vaccine

Zhang Y. et al, (2026), Eclinicalmedicine, 94

Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial

Kelly E. et al, (2026), Journal of Infection, 92

Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials

Bijukchhe SM. et al, (2026), Lancet Infectious Diseases

Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial

Janani L. et al, (2025), Journal of Infection, 91

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006)

Li G. et al, (2025), Vaccine, 62

MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines

Amini A. et al, (2025), Science Immunology, 10

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil

Costa Clemens SA. et al, (2025), Mayo Clinic Proceedings Innovations Quality and Outcomes, 9

Interplay between the gut microbiome and typhoid fever: insights from endemic countries and a controlled human infection model

Ashton PM. et al, (2025), Microbiome, 13

Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study

Feng S. et al, (2025), Journal of Infection, 90

Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial

Conlin K. et al, (2025), Vaccine, 45

Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa

Chanda C. et al, (2025), The Lancet Microbe

PROTECTION CONFERRED BY A SINGLE DOSE OF TYPHOID CONJUGATE VACCINE AMONG BANGLADESHI CHILDREN AFTER FIVE YEARS OF VACCINATION: ANALYSIS OF A CLUSTER RANDOMIZED CONTROLLED TRIAL

Khanam F. et al, (2025), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 112

Modelling Salmonella Typhi in high-density urban Blantyre neighbourhood, Malawi, using point pattern methods

Khaki JJ. et al, (2024), Scientific Reports, 14

Five-Year Vaccine Protection Following a Single Dose of Vi-Tetanus Toxoid Conjugate Vaccine in Bangladeshi Children: A Cluster Randomised Trial

Qadri F. et al, (2024)

5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial

Qadri F. et al, (2024), The Lancet, 404, 1419 - 1429

Pathogen diversity and antimicrobial resistance transmission of Salmonella enterica serovars Typhi and Paratyphi A in Bangladesh, Nepal, and Malawi: a genomic epidemiological study

Dyson ZA. et al, (2024), The Lancet Microbe, 5

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study

Jackson S. et al, (2024), The Lancet Microbe, 5, 655 - 668

Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age

Bijukchhe SM. et al, (2024), Vaccine, 42, 2018 - 2025

Evaluating the relationship between ciprofloxacin prescription and non-susceptibility in Salmonella Typhi in Blantyre, Malawi: an observational study

Ashton PM. et al, (2024), The Lancet Microbe, 5, e226 - e234

Direct inference and control of genetic population structure from RNA sequencing data

Fachrul M. et al, (2023), Communications Biology, 6

Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) — a protocol for two parallel, open-label, randomised controlled trials

Kelly S. et al, (2023), Trials, 24

Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial

Hill M. et al, (2023), BMJ Open, 13

SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood

Lugar M. et al, (2023), JAMA, 330, 1151 - 1160

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial

Kelly E. et al, (2023), Journal of Infection, 87, 230 - 241

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

Liu X. et al, (2023), Journal of Infection, 87, 18 - 26

More publications